Market Research Report
MediPoint: Bone Grafts & Substitutes - Asia-Pacific Forecast and Market Analysis
|Published by||GlobalData||Product code||296028|
|Published||Content info||34 Pages
Delivery time: 1-2 business days
|MediPoint: Bone Grafts & Substitutes - Asia-Pacific Forecast and Market Analysis|
|Published: March 3, 2017||Content info: 34 Pages||
Autograft bone is considered the gold-standard treatment, as it confers complete histocompatibility while possessing all three parts of the bone healing triad: osteoconductive, osteoinductive, and osteogenic healing potentials. However, the amount of autograft bone available is often insufficient, and the graft harvesting procedure presents a number of comorbidities including donor site pain and infection. Due to these drawbacks, a soaring demand for alternatives to autograft bone has arisen globally.
Conditions for spontaneous bone healing after trauma or orthopedic surgery are not always ideal. Even with the efficacy of modern internal fixation and spinal fusion techniques, factors such as poor vascularity, malnutrition, and substantial bone or soft tissue loss can impede effective bone growth. As a result, the market for bone grafts and substitutes has emerged and exploded.
Asia-Pacific (APAC) bone grafts and substitutes market was estimated at US$351.7M in 2016 across the seven markets (Australia, China, India, Japan, New Zealand, South Korea, and Taiwan) covered in this report. By the end of the forecast period in 2023, it is estimated that the market will grow to approximately US$502.1M at a Compound Annual Growth Rate (CAGR) of 5.2%.
Key drivers of the bone grafts and substitutes market in the forecast period are -
APAC bone grafts and substitutes market is projected to grow at a CAGR of 5.2% during the forecast period. Japan represented the largest portion of the market in 2016, holding nearly 50.0% of the regional revenue, and is expected to maintain this dominance through the forecast period. China is expected to be the fastest-growing market through 2023, at a CAGR of 7.0%, while the slowest growth will be observed in Japan at a CAGR of 3.8%.
The market for bone grafts and substitutes is highly populated, with players ranging from small orthobiologics startups to medical device multinationals. Three major players-Medtronic, DePuy Synthes, and Stryker-dominate the global space due to the companies' far-reaching distribution networks and established presence in complementary markets, including spinal fusion and trauma fixation. Additionally, as hospital purchasing organizations and healthcare providers seek cost-saving measures, the largest players in the bone grafts and substitutes market offer a full portfolio of products to meet all bone graft needs in bundled deals.
The report "MediPoint: Bone Grafts & Substitutes - Asia-Pacific Forecast and Market Analysis", focuses on the market outlook for bone graft and substitute products in Asia-Pacific (APAC: Australia, China, India, Japan, New Zealand, South Korea, and Taiwan). The analysis discusses the major drivers and barriers of adoption, and provides an in-depth understanding of the future outlook for this market by segment and geography.
Companies mentioned in this report: DePuy Synthes, Medtronic, Stryker Zimmer Biomet.
The report will enable you to -